VERVE THERAPEUTICS INC (VERV) Stock Analyst Earnings Estimates
NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.94M | 11.758M 506.08% | 24.275M 106.46% | 16.508M -32.00% | 10.183M -38.31% | 20.477M 101.09% | 10.073M -50.81% | 30.974M 207.50% | 65.433M 111.25% | 131.07M 100.31% | 229.5M 75.10% | ||
| EBITDA YoY % growth | -85.53M -117.63% | -162.89M -90.45% | -217.669M -33.63% | -245.656M -12.86% | -336.289M -36.89% | -384.191M -14.24% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.07M -114.30% | -165.69M -90.30% | -223.124M -34.66% | -240.738M -7.89% | -280.728M -16.61% | -317.412M -13.07% | -315.323M 0.66% | -361.039M -14.50% | -369.266M -2.28% | -330.956M 10.37% | -207.06M 37.44% | -150.96M 27.09% | |
| Operating Margin | N/A | -8,540.72% | -1,897.64% | -991.71% | -1,700.56% | -3,117.08% | -1,539.89% | -3,584.23% | -1,192.18% | -505.79% | -157.98% | -65.78% | |
| EPS YoY % growth | N/A | -2.92 38.44% | -3.12 -6.85% | -2.55 18.30% | -2.96 -16.31% | -3.00 -1.20% | -2.87 4.38% | -3.25 -13.42% | -3.64 -11.81% | -3.74 -2.76% | -4.48 -19.78% | -3.74 16.40% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.71 -2.89% | -0.75 -27.68% | -0.77 -29.91% | -0.78 -32.87% | -0.75 -5.13% |
| Revenue Q2Q % growth | 4.042M -21.41% | 3.869M -32.06% | 3.665M -45.23% | 4.073M -40.67% | 4.581M 13.33% |
| EBITDA Q2Q % growth | -76.5M -57.75% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -65.255M -20.96% | -68.438M -20.40% | -71.128M -20.89% | -73.079M -28.41% | -71.208M -9.12% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.59 18.06% | -0.71 | 0.12 | 17.01% |
| Q2 2024 Q2Q % growth | -0.59 32.18% | -0.70 | 0.11 | 15.43% |
| Q1 2024 Q2Q % growth | -0.59 29.76% | -0.73 | 0.14 | 18.87% |
| Q4 2023 Q2Q % growth | -0.69 -2.99% | -0.84 | 0.15 | 17.70% |
| Q3 2023 Q2Q % growth | -0.72 8.86% | -0.94 | 0.22 | 23.11% |
| Q2 2023 Q2Q % growth | -0.87 -3.57% | -0.94 | 0.07 | 7.09% |
| Q1 2023 Q2Q % growth | -0.84 -35.48% | -0.79 | -0.05 | -5.72% |
| Q4 2022 Q2Q % growth | -0.67 -3.08% | -0.78 | 0.11 | 14.10% |
| Q3 2022 Q2Q % growth | -0.79 -68.09% | -0.75 | -0.04 | -5.27% |
| Q2 2022 Q2Q % growth | -0.84 87.39% | -0.66 | -0.18 | -27.26% |
| Q1 2022 Q2Q % growth | -0.62 | -0.67 | 0.05 | 7.50% |
| Q4 2021 Q2Q % growth | -0.65 | -0.56 | -0.09 | -15.56% |
| Q3 2021 Q2Q % growth | -0.47 | -0.46 | -0.01 | -1.83% |
| Q2 2021 Q2Q % growth | -6.66 | -0.50 | -6.16 | -1,232.53% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 6.865M 120.24% | 2.866M | 3.999M | 139.53% |
| Q2 2024 Q2Q % growth | 6.692M 219.73% | 2.448M | 4.244M | 173.37% |
| Q1 2024 Q2Q % growth | 5.695M 305.63% | 2.066M | 3.629M | 175.65% |
| Q4 2023 Q2Q % growth | 5.143M 409.21% | 1.192M | 3.951M | 331.46% |
| Q3 2023 Q2Q % growth | 3.117M 235.16% | 982.943K | 2.134M | 217.11% |
| Q2 2023 Q2Q % growth | 2.093M | 771.885K | 1.321M | 171.15% |
| Q1 2023 Q2Q % growth | 1.404M | 524.576K | 879.424K | 167.64% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0.44% | 0.85% | 0.4% | 1.58% |
| Revenue | 11.11% | 20.91% | 4.55% | 11.8% |